NASDAQ:ESPR Esperion Therapeutics (ESPR) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free ESPR Stock Alerts $2.37 +0.25 (+11.79%) (As of 05:14 PM ET) Add Compare Share Share Today's Range$2.13▼$2.5350-Day Range$1.84▼$3.2452-Week Range$0.70▼$3.40Volume45.76 million shsAverage Volume6.96 million shsMarket Capitalization$448.88 millionP/E RatioN/ADividend YieldN/APrice Target$9.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Esperion Therapeutics alerts: Email Address Esperion Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.40 Rating ScoreUpside/Downside277.9% Upside$9.33 Price TargetShort InterestHealthy11.04% of Float Sold ShortDividend StrengthN/ASustainability-2.76Upright™ Environmental ScoreNews Sentiment0.11Based on 19 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.68) to $0.30 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.87 out of 5 starsMedical Sector229th out of 903 stocksPharmaceutical Preparations Industry101st out of 420 stocks 3.2 Analyst's Opinion Consensus RatingEsperion Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageEsperion Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted11.04% of the float of Esperion Therapeutics has been sold short.Short Interest Ratio / Days to CoverEsperion Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Esperion Therapeutics has recently decreased by 6.63%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEsperion Therapeutics does not currently pay a dividend.Dividend GrowthEsperion Therapeutics does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEsperion Therapeutics has received a 53.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Ezetimibe", "Clinical research services for pulmonary hearth diseases", and "Bempedoic acid" products. See details.Environmental SustainabilityThe Environmental Impact score for Esperion Therapeutics is -2.76. Previous Next 1.7 News and Social Media Coverage News SentimentEsperion Therapeutics has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Esperion Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 46 people have searched for ESPR on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.MarketBeat FollowsOnly 16 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -24% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Esperion Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.00% of the stock of Esperion Therapeutics is held by insiders.Percentage Held by Institutions47.39% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Esperion Therapeutics are expected to grow in the coming year, from ($0.68) to $0.30 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Esperion Therapeutics is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Esperion Therapeutics is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaIncredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About Esperion Therapeutics Stock (NASDAQ:ESPR)Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Read More ESPR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ESPR Stock News HeadlinesMay 7, 2024 | investorplace.comESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | investorplace.comWhy Is Esperion Therapeutics (ESPR) Stock Up 13% Today?May 7, 2024 | Crypto 101 Media (Ad)Elon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.May 7, 2024 | washingtonpost.comEsperion Therapeutics: Q1 Earnings SnapshotMay 7, 2024 | americanbankingnews.comZacks Research Comments on Esperion Therapeutics, Inc.'s Q1 2026 Earnings (NASDAQ:ESPR)May 7, 2024 | globenewswire.comEsperion Reports First Quarter 2024 Financial ResultsMay 5, 2024 | americanbankingnews.comEsperion Therapeutics (ESPR) Set to Announce Earnings on TuesdayMay 2, 2024 | americanbankingnews.comQ4 2025 Earnings Forecast for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Issued By Zacks ResearchMay 7, 2024 | Crypto 101 Media (Ad)Elon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.May 1, 2024 | nasdaq.comEsperion Therapeutics, Inc. Common Stock (ESPR)May 1, 2024 | americanbankingnews.comFY2025 EPS Estimates for Esperion Therapeutics, Inc. Decreased by Zacks Research (NASDAQ:ESPR)April 29, 2024 | globenewswire.comEsperion to Participate in Upcoming May Investor ConferencesApril 23, 2024 | finance.yahoo.comEsperion to Report First Quarter 2024 Financial Results on May 7April 21, 2024 | finance.yahoo.com11 Best Low Price Pharma Stocks To Invest InApril 8, 2024 | msn.comEsperion stock jumps as non-statin therapy shows clinical benefits across diverse patient groupsApril 7, 2024 | globenewswire.comEsperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with ObesityApril 3, 2024 | msn.comSignet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On WednesdayApril 1, 2024 | globenewswire.comEsperion to Ring Nasdaq Opening Bell Today, April 1, 2024March 26, 2024 | finance.yahoo.comEsperion to Participate in 23rd Annual Needham Virtual Healthcare ConferenceMarch 26, 2024 | msn.comWhy Is Heart Disease-Focused Esperion Therapeutics Stock Trading Higher On Monday?March 25, 2024 | globenewswire.comEsperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24March 25, 2024 | msn.comEsperion Therapeutics, Masimo And Other Big Stocks Moving Higher In Monday's Pre-Market SessionMarch 23, 2024 | money.usnews.comEsperion Therapeutics Inc.March 22, 2024 | finance.yahoo.comU.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseMarch 22, 2024 | businesswire.comU.S. FDA Approves Broad New Labels for Esperion's NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseMarch 22, 2024 | globenewswire.comU.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseMarch 22, 2024 | marketwatch.comEsperion Therapeutics Gets CHMP Positive Opinion for Cholesterol MedicationsSee More Headlines Receive ESPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today5/07/2024Next Earnings (Confirmed)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ESPR CUSIPN/A CIK1434868 Webwww.esperion.com Phone(734) 887-3903FaxN/AEmployees240Year FoundedN/APrice Target and Rating Average Stock Price Target$9.33 High Stock Price Target$16.00 Low Stock Price Target$4.00 Potential Upside/Downside+293.8%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-209,250,000.00 Net Margins-179.87% Pretax Margin-179.87% Return on EquityN/A Return on Assets-91.62% Debt Debt-to-Equity RatioN/A Current Ratio1.29 Quick Ratio0.87 Sales & Book Value Annual Sales$116.33 million Price / Sales3.86 Cash FlowN/A Price / Cash FlowN/A Book Value($3.85) per share Price / Book-0.62Miscellaneous Outstanding Shares189,400,000Free Float187,507,000Market Cap$448.88 million OptionableOptionable Beta0.89 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Sheldon L. Koenig (Age 58)President, CEO & Director Comp: $1.28MDr. JoAnne Micale Foody FACC (Age 59)M.D., Chief Medical Officer Comp: $856.87kMr. Eric J. Warren R.Ph. (Age 52)Chief Commercial Officer Comp: $718.86kMr. Benjamin Halladay M.B.A. (Age 38)Chief Financial Officer Mr. Glenn P. Brame (Age 66)Chief Technical Operations Officer Mr. Benjamin O. Looker J.D. (Age 42)General Counsel & Corporate Secretary Comp: $550.35kTiffany Aldrich M.B.A.Associate Director of Corporate CommunicationsMs. Betty Jean SwartzChief Business OfficerMore ExecutivesKey CompetitorsRevance TherapeuticsNASDAQ:RVNCAmarinNASDAQ:AMRNLexicon PharmaceuticalsNASDAQ:LXRXNature's Sunshine ProductsNASDAQ:NATRMereo BioPharma GroupNASDAQ:MREOView All CompetitorsInsiders & InstitutionsSG Americas Securities LLCBought 25,756 shares on 5/7/2024Ownership: 0.014%GSA Capital Partners LLPSold 679,020 shares on 5/3/2024Ownership: 0.237%Boomfish Wealth Group LLCBought 29,895 shares on 5/3/2024Ownership: 0.016%BNP Paribas Financial MarketsSold 8,022 shares on 5/1/2024Ownership: 0.008%Mesirow Financial Investment Management Inc.Bought 20,000 shares on 4/26/2024Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions ESPR Stock Analysis - Frequently Asked Questions Should I buy or sell Esperion Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ESPR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares. View ESPR analyst ratings or view top-rated stocks. What is Esperion Therapeutics' stock price target for 2024? 5 brokerages have issued 1 year target prices for Esperion Therapeutics' shares. Their ESPR share price targets range from $4.00 to $16.00. On average, they anticipate the company's stock price to reach $9.33 in the next year. This suggests a possible upside of 277.9% from the stock's current price. View analysts price targets for ESPR or view top-rated stocks among Wall Street analysts. How have ESPR shares performed in 2024? Esperion Therapeutics' stock was trading at $2.99 at the beginning of the year. Since then, ESPR shares have decreased by 17.4% and is now trading at $2.47. View the best growth stocks for 2024 here. Are investors shorting Esperion Therapeutics? Esperion Therapeutics saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 18,600,000 shares, a decline of 6.6% from the March 31st total of 19,920,000 shares. Based on an average daily volume of 6,230,000 shares, the short-interest ratio is presently 3.0 days. Currently, 11.0% of the company's stock are short sold. View Esperion Therapeutics' Short Interest. When is Esperion Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our ESPR earnings forecast. How were Esperion Therapeutics' earnings last quarter? Esperion Therapeutics, Inc. (NASDAQ:ESPR) released its quarterly earnings data on Tuesday, February, 27th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.03. The biopharmaceutical company had revenue of $32.25 million for the quarter, compared to the consensus estimate of $26.84 million. During the same quarter last year, the business posted ($0.76) EPS. What ETF holds Esperion Therapeutics' stock? Jacob Forward ETF holds 55,136 shares of ESPR stock, representing 3.72% of its portfolio. What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO? 20 employees have rated Esperion Therapeutics Chief Executive Officer Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among the company's employees. What other stocks do shareholders of Esperion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn). Who are Esperion Therapeutics' major shareholders? Esperion Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wasatch Advisors LP (4.82%), GSA Capital Partners LLP (0.24%), Boomfish Wealth Group LLC (0.02%), Summit Financial LLC (0.01%), SG Americas Securities LLC (0.01%) and Capital Advisors Wealth Management LLC (0.01%). Insiders that own company stock include Benjamin Looker, Eric Warren, J Martin Carroll, Joanne M Foody, Sheldon L Koenig and Target N V Biotech. View institutional ownership trends. How do I buy shares of Esperion Therapeutics? Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ESPR) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersAI “wealth window” is closing June 25thParadigm PressThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe asset beating inflation by 4xColonial MetalsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
